WallStreetZenWallStreetZen

NASDAQ: PLRX
Pliant Therapeutics Inc Stock Ownership - Who owns Pliant Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Pliant Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Lily CheungChief Human Resource Officer2026-01-207,534$1.28
$9.64kSell
Bernard CouliePresident and CEO2026-01-2089,375$1.28
$114.40kSell
Keith Lamont CummingsChief Financial Officer2026-01-2024,002$1.28
$30.72kSell
Minnie KuoChief Operating Officer2026-01-206,917$1.28
$8.85kSell

1 of 1

PLRX insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when PLRX insiders and whales buy or sell their stock.

PLRX Shareholders

What type of owners hold Pliant Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Matthew G. Robinson25.95%16,069,177$18.96MInsider
Tang Capital Management LLC9.92%6,143,132$7.25MInstitution
Third Rock Ventures III LP7.26%4,495,238$5.30MInsider
Citadel Advisors LLC5.21%3,226,599$3.81MInstitution
Blue Owl Capital Holdings LP4.80%2,969,199$3.50MInstitution
Adar1 Capital Management LLC4.17%2,585,126$3.05MInstitution
Acadian Asset Management LLC3.90%2,416,508$2.85MInstitution
Vanguard Capital Management LLC3.78%2,343,101$2.76MInstitution
Two Sigma Investments LP3.64%2,253,138$2.66MInstitution
Monaco Asset Management Sam3.13%1,938,747$2.29MInstitution

1 of 3

PLRX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
PLRX65.47%34.53%Net Selling
MCRB3.32%96.68%Net SellingNet Selling
XBIT6.53%46.67%
PMVP58.61%41.39%Net Selling
DOMH7.11%68.39%Net Selling
View Top Biotech Stocks

Pliant Therapeutics Stock Ownership FAQ

Who owns Pliant Therapeutics?

Pliant Therapeutics (NASDAQ: PLRX) is owned by 80.23% institutional shareholders, 42.31% Pliant Therapeutics insiders, and 0.00% retail investors. Matthew G. Robinson is the largest individual Pliant Therapeutics shareholder, owning 16.07M shares representing 25.95% of the company. Matthew G. Robinson's Pliant Therapeutics shares are currently valued at $18.48M.

If you're new to stock investing, here's how to buy Pliant Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.